mirtazapine has been researched along with Recrudescence in 25 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 7.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 5.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| " Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication." | 5.30 | A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes ( Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N, 2019) |
| " Authors report a case of a 65-year old male patient who was treated with venlafaxine-mirtazapine combination for recurrent depression." | 3.79 | [Antidepressant treatment associated hyponatremia -- case report]. ( Bognár, Z; Gazdag, G; Vonyik, G, 2013) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 3.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| " Overall, 35-42% of esmirtazapine-treated patients had adverse events (AEs) versus 29% in the placebo group." | 2.80 | Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. ( Ivgy-May, N; Krystal, A; Roth, T; Ruwe, F, 2015) |
| "Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation." | 2.78 | Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Mirtazapine was then initiated for residual depressive symptoms." | 2.71 | Migraine headache prophylaxis and treatment with low-dose mirtazapine. ( Lévy, E; Margolese, HC, 2003) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| "The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms." | 1.62 | Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment. ( Frankle, WG; Lequesne, E; Rohs, A; Zhang, E, 2021) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 1.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "Mirtazapine is a noradrenergic with specific selective serotoninergic antidepressant." | 1.30 | Mirtazapine in recurrent brief depression. ( Aschauer, HN; de Zwaan, M; Kasper, S; Pezawas, L; Stamenkovic, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, E | 1 |
| Lequesne, E | 1 |
| Rohs, A | 1 |
| Frankle, WG | 1 |
| Sado, M | 1 |
| Wada, M | 1 |
| Ninomiya, A | 1 |
| Nohara, H | 1 |
| Kosugi, T | 1 |
| Arai, M | 1 |
| Endo, R | 1 |
| Mimura, M | 1 |
| Duffy, L | 1 |
| Bacon, F | 1 |
| Clarke, CS | 1 |
| Donkor, Y | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 1 |
| Kessler, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Lewis, G | 2 |
| Mangin, D | 1 |
| Marston, L | 1 |
| Moore, M | 1 |
| Nazareth, I | 1 |
| Wiles, N | 1 |
| Bognár, Z | 1 |
| Vonyik, G | 1 |
| Gazdag, G | 1 |
| Warden, D | 2 |
| Trivedi, MH | 3 |
| Carmody, T | 1 |
| Toups, M | 1 |
| Zisook, S | 3 |
| Lesser, I | 1 |
| Myers, A | 1 |
| Kurian, KR | 1 |
| Morris, D | 1 |
| Rush, AJ | 3 |
| Ivgy-May, N | 1 |
| Ruwe, F | 1 |
| Krystal, A | 1 |
| Roth, T | 1 |
| Naples, JG | 1 |
| Kotlarczyk, MP | 1 |
| Perera, S | 1 |
| Greenspan, SL | 1 |
| Hanlon, JT | 1 |
| Sokolover, N | 1 |
| Merlob, P | 1 |
| Klinger, G | 1 |
| Benedict, A | 1 |
| Arellano, J | 1 |
| De Cock, E | 1 |
| Baird, J | 1 |
| Grønli, O | 1 |
| Stensland, GØ | 1 |
| Wynn, R | 1 |
| Olstad, R | 1 |
| Mischo, M | 1 |
| Nigg, C | 1 |
| Kiss, A | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Wisniewski, SR | 2 |
| Gaynes, BN | 1 |
| Howland, RH | 1 |
| Balasubramani, GK | 2 |
| Fava, M | 1 |
| Sung, SC | 1 |
| Kurian, B | 1 |
| Lévy, E | 1 |
| Margolese, HC | 1 |
| Nash, JR | 1 |
| Wilson, SJ | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
| Bavbek, N | 1 |
| Kargili, A | 1 |
| Akcay, A | 1 |
| Kaya, A | 1 |
| Elstner, S | 1 |
| Burian, R | 1 |
| Diefenbacher, A | 1 |
| Stamenkovic, M | 1 |
| Pezawas, L | 1 |
| de Zwaan, M | 1 |
| Aschauer, HN | 1 |
| Kasper, S | 1 |
| Falkai, P | 1 |
| Nierenberg, AA | 2 |
| Wright, EC | 1 |
| Moustgaard, G | 1 |
| Good, C | 1 |
| Petersen, C | 1 |
| Thase, ME | 1 |
| Keller, MB | 1 |
| Panagides, J | 1 |
| Delgado, PL | 1 |
| Moreno, FA | 1 |
| Onate, L | 1 |
| Gelenberg, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00506389] | Phase 3 | 419 participants (Actual) | Interventional | 2007-06-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
LPS was defined as the time in minutes from lights out to the first 20 consecutive epochs scored as sleep as measured by PSG. LPS was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 28.7 |
| Esmirtazapine 4.5 mg | 26.1 |
| Placebo | 40.5 |
TST was defined as the total amount of time in minutes that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 6 week In-Treatment Period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were available was used in the analysis. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 384.6 |
| Esmirtazapine 4.5 mg | 384.6 |
| Placebo | 351.6 |
WASO was defined as the total objective time awake after the onset of persistent sleep until the end of the 8-hour sleep cycle period as measured by polysomnography (PSG). WASO was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 45.6 |
| Esmirtazapine 4.5 mg | 45.5 |
| Placebo | 76.1 |
4 reviews available for mirtazapine and Recrudescence
| Article | Year |
|---|---|
[Depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 2010 |
[Depression in family practice].
Topics: Age Factors; Aged; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Disord | 2007 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
Evolution of remission as the new standard in the treatment of depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Depressive Disorder; F | 1999 |
8 trials available for mirtazapine and Recrudescence
| Article | Year |
|---|---|
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Meth | 2019 |
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso | 2014 |
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2015 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab | 2013 |
Migraine headache prophylaxis and treatment with low-dose mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Mianserin; Migraine Di | 2003 |
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.
Topics: Adult; Chronic Disease; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; | 2001 |
Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; | 2002 |
13 other studies available for mirtazapine and Recrudescence
| Article | Year |
|---|---|
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment.
Topics: Adult; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Clozapine; COVID-19; COVID-19 Nuclei | 2021 |
Does the rapid response of an antidepressant contribute to better cost-effectiveness? Comparison between mirtazapine and SSRIs for first-line treatment of depression in Japan.
Topics: Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder; Humans; Japan; Mirtazapine | 2019 |
[Antidepressant treatment associated hyponatremia -- case report].
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyc | 2013 |
Non-tricyclic and Non-selective Serotonin Reuptake Inhibitor Antidepressants and Recurrent Falls in Frail Older Women.
Topics: Accidental Falls; Aged, 80 and over; Antidepressive Agents; Bupropion; Female; Frail Elderly; Humans | 2016 |
Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Body Temperature Regulation; Female; Fol | 2008 |
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Topics: Cost-Benefit Analysis; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Duloxetine H | 2010 |
Neurotrophic factors in serum following ECT: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Combined Modality Therapy; Cyclohexanols; Depressi | 2009 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drug Administration Schedule; Hu | 2003 |
Recurrent hyponatremia associated with citalopram and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Diagnosis, Di | 2006 |
Mirtazapine in recurrent brief depression.
Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; | 1998 |
Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Drug Therapy, Combin | 2000 |
SSRI and mirtazapine in PTSD.
Topics: Adrenergic alpha-Antagonists; Child; Child Abuse, Sexual; Drug Therapy, Combination; Female; Humans; | 2001 |
[Depressive disorders. A third have a chronic course].
Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Dr | 2001 |